Chimeric antigen receptor (CAR) T‐cell therapy is a promising immunotherapeutic treatment
concept that is changing the treatment approach to hematologic malignancies. The …

Chimeric antigen receptor (CAR) T‑cells are genetically engineered to give T‑cells the ability
to attack specific cancer cells, and to improve outcome of patients with refractory/relapsed …

Purpose To describe the modern incidence and predictors of ICU admission for adult
patients newly diagnosed with a hematologic malignancy. Methods We conducted a …

Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and
treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA …

The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic
improvement increasing the prognosis for patients with a variety of hematological …

Combined advances in haematopoietic cell transplantation (HCT) and intensive care
management have improved the survival of patients with haematological malignancies …

Cancer immunotherapy has now entered clinical practice and has reshaped the standard of
care for many cancer patients. With these new strategies, specific toxicities have emerged …

A cutting-edge approach in cell-based immunotherapy for combating resistant cancer
involves genetically engineered chimeric antigen receptor T (CAR-T) lymphocytes. In recent …

Immunosuppressed patients, particularly those with cancer, represent a momentous and
increasing portion of the population, especially as cancer incidence rises with population …

Background Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising
treatment option for relapsed or refractory B-cell malignancies and multiple myeloma …